[P2–004]: THE SAFETY AND EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) FOR ALZHEIMER'S DISEASE: A META‐ANALYSIS

elenbecestat 50 mg dosed 2 hours before donepezil 10 mg, according to a randomized treatment sequence with 21-day washout between treatments. Pharmacokinetic assessments of drugs, including elenbecestat andmetabolitesM1,M2, andM5,were conducted.Results:Coadministration of elenbecestat and itraconazole resulted in increases in elenbecestat Cmax, AUC(0-inf), and t1/2 compared with administration of elenbecestat alone (Figures). The Cmax of all elenbecestat metabolites decreased with itraconazole co-administration. Coadministration of elenbecestat and rifampin resulted in relatively no change in Cmax or t1/2, a minor decrease in AUC(0-inf), along with pronounced decreases inM2 andM5. In Part B, elenbecestat and digoxin co-administration increased digoxin Cmax slightly, but no changes in overall systemic exposure (AUC) were observed. Co-administration of elenbecestat and donepezil at the same time resulted in non-clinically meaningful increases in Cmax and AUC(0-inf). However, no notable changes in elenbecestat exposureoccurredwhenadministered 2 hours before donepezil. Conclusions:Results indicate that itraconazole’s interaction was primarily due to CES2 inhibition, therefore, no restrictions or dose adjustments are warranted for elenbecestat when co-administered with CYP3A inhibitors. Furthermore, no dose adjustments are necessary for elenbecestat when co-administered with Pgp substrates or donepezil. P2-004 THE SAFETYAND EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) FOR ALZHEIMER’S DISEASE: A META-ANALYSIS Ross Penninkilampi, Guy D. Eslick, The University of Sydney, Sydney, Australia; University of Sydney, Sydney, Australia. Contact e-mail: r.penninkilampi@student.unsw.edu.au